Research programme: rheumatoid arthritis therapy - GEMACBIOAlternative Names: GEM RA; Rheumatoid arthritis therapy research programme - GEMACBIO
Latest Information Update: 16 Jul 2016
At a glance
- Originator GEMACBIO
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Rheumatic disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Rheumatic-disorders in France
- 11 Aug 2005 Preclinical trials in Rheumatic disorders in France (unspecified route)